Ernexa Therapeutics (ERNAW) Capital Expenditures (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Capital Expenditures data on file, last reported at $2000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 300.0% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40000.0 (up 138.46% YoY) and the FY2025 annual result came in at $37000.0, up 1950.0% from the prior year.
• Capital Expenditures fell to $2000.0 in Q1 2026, from $39000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q3 2023 to a low of -$2.9 million in Q4 2023.
• A 5-year average of $46800.0 and a median of $43000.0 in 2022 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 5551.16% in 2023, down 881.62% in 2023.
• Tracing ERNAW's Capital Expenditures over 5 years: stood at $370000.0 in 2022, then plunged by 881.62% to -$2.9 million in 2023, then surged by 99.97% to -$1000.0 in 2024, then surged by 4000.0% to $39000.0 in 2025, then plunged by 94.87% to $2000.0 in 2026.
• The last three Capital Expenditures figures came in at $2000.0 (Q1 2026), $39000.0 (Q4 2025), and -$1000.0 (Q3 2025), per Business Quant data.